卫材FY2026一季度收入超预期约9.5%，但同一财报复盘已在本批出现

Trump says Iran talks to begin on Monday amid cycle of threats and pullbacks
Introduction & Market Context
Eisai Co., Ltd. presented its Q1 FY2026 financial results on August 3, 2026, reporting revenue and profit growth that exceeded expectations, driven by strong performance across its three flagship pharmaceutical products. Despite beating revenue forecasts by approximately 9.5%, the company’s shares fell 3.56% to $4,656, suggesting investor caution about the sustainability of growth amid rising investments in commercial infrastructure and research and development.
The Japanese pharmaceutical company reported first-quarter revenue of ¥234.3 billion, up 15.6% year-over-year and well ahead of the ¥214.01 billion analyst forecast. Operating profit climbed 19.2% to ¥24.7 billion, while net profit increased 26% to ¥18.2 billion, demonstrating improving operational leverage as the company’s "3L" products—LENVIMA, DAYVIGO, and LEQEMBI—gained momentum across global markets.
Quarterly Performance Highlights
Eisai’s Q1 FY2026 results reflected broad-based pharmaceutical business growth, with revenue reaching 27% of the full-year forecast and operating profit achieving 35% of the annual target, indicating the company is pacing ahead of a linear trajectory toward its fiscal year goals.
As detailed in the company’s consolidated financial statement, the pharmaceutical business generated ¥230.9 billion in revenue, up 16.4% year-over-year, while the "Other business" segment declined 18.4% to ¥3.4 billion.
The company’s gross profit reached ¥183.2 billion, representing a 78.2% gross margin, though the cost of sales ratio increased by 0.8 percentage points to 21.8%. Research and development expenses totaled ¥43.7 billion, or 18.7% of revenue, up 12.7% year-over-year, reflecting continued investment in key pipeline programs including LEQEMBI and the anti-MTBR tau antibody etalanetug.
Operating profit margin improved to 10.6%, up 0.3 percentage points from the prior year, demonstrating that revenue growth is outpacing cost increases. Management noted this marked the first time the company achieved profitability in its commercial businesses when excluding LEQEMBI R&D spending.
The revenue increase of ¥31.7 billion was primarily attributed to the 3L products, as illustrated in the company’s waterfall analysis.
LENVIMA contributed ¥13.4 billion to the revenue increase (+16%), DAYVIGO added ¥5.2 billion (+38%), and LEQEMBI provided ¥6.2 billion (+27%). Products excluding the 3L portfolio contributed an additional ¥7.7 billion, demonstrating diversification beyond the company’s flagship brands.
Regional Performance Analysis
The Americas pharmaceutical business delivered the strongest regional growth, with revenue climbing 22.3% to ¥86.6 billion, representing 36.9% of total pharmaceutical revenue. The United States specifically generated ¥83.8 billion, up 21.6% year-over-year, with segment profit reaching ¥51.9 billion and a robust 60% profit margin.
China pharmaceutical business revenue increased 16.6% to ¥42.5 billion, though constant currency growth was flat at -0.3%, reflecting the impact of favorable foreign exchange rates. The region maintained a strong 49.8% segment profit margin at ¥21.2 billion.
EMEA pharmaceutical business posted 24.4% revenue growth to ¥23.6 billion, with segment profit surging 51.8% to ¥12.5 billion, yielding a 52.7% profit margin. The East Asia Global South region grew 25.3% to ¥20.2 billion in revenue.
Japan pharmaceutical business, the company’s home market, showed more modest growth of 3.4% to ¥57.9 billion, representing 24.7% of total pharmaceutical revenue, with segment profit of ¥21.0 billion and a 36.3% margin.
Three Pillars of Growth
LENVIMA: Sustained Oncology Foundation
LENVIMA, Eisai’s oral multi-kinase inhibitor with seven indications across five cancer types, generated ¥97.3 billion in Q1 revenue, up 16% year-over-year. The product has now contributed to treating approximately 620,000 patients across 83 countries and territories over 11 years since launch.
The Americas region led LENVIMA growth with ¥66.5 billion in revenue, while EMEA contributed ¥15.1 billion, up 36.6% year-over-year. The company highlighted that LENVIMA maintains top market share in the tyrosine kinase inhibitor category for advanced renal cell carcinoma, endometrial carcinoma, hepatocellular cancer, and radioactive iodine-refractory differentiated thyroid cancer.
A key near-term catalyst is the pending U.S. FDA decision on a new indication for advanced renal cell carcinoma patients whose disease progressed after anti-PD-1/L1 therapy, based on the LITESPARK-011 study combining WELIREG® with LENVIMA. The FDA’s Prescription Drug User Fee Act (PDUFA) date is set for October 4, 2026.
DAYVIGO: Accelerating Global Expansion
DAYVIGO (lemborexant), Eisai’s dual orexin receptor antagonist for insomnia treatment, achieved ¥18.9 billion in Q1 revenue, representing 38% year-over-year growth and marking accelerating momentum across all regions.
Japan remained DAYVIGO’s largest market with ¥12.4 billion in revenue, where the product maintained the number one share in both sales and patient numbers by leveraging its strength as a dual orexin receptor antagonist for improving sleep onset and maintenance. The Americas region grew 74.5% to ¥3.3 billion, while China revenue surged from a small base to ¥1.4 billion.
The company completed regulatory submissions in the United Kingdom (MHRA) and European Union (EMA) in July 2026, with approvals expected to support further geographic expansion toward the full-year forecast of ¥73.5 billion.
LEQEMBI: Technology-Driven Alzheimer’s Platform
LEQEMBI (lecanemab-irmb), Eisai’s anti-amyloid beta antibody for early Alzheimer’s disease, generated ¥29.3 billion in Q1 revenue, up 27% year-over-year, with contributions from all regions. The product is now approved in 53 countries and territories, including Japan, the United States, China, and the European Union.
The Americas led LEQEMBI sales with ¥15.5 billion, up 70.5% year-over-year, driven by an increased number of early AD patients and growing blood-based biomarker testing volumes. Japan contributed ¥6.1 billion despite a 15% drug price reduction implemented in November 2025, demonstrating underlying demand strength.
China revenue of ¥4.8 billion reflected a year-over-year decline of 37.3%, primarily due to a one-time impact in the prior year period. The company noted that reimbursement has started under several commercial insurance programs, with broader coverage expected in the second half of the fiscal year. EMEA and East Asia Global South regions contributed ¥2.9 billion combined.
Strategic Initiatives: LEQEMBI IQLIK and Diagnostic Evolution
A major development highlighted in the presentation was the July 13, 2026 U.S. approval of LEQEMBI IQLIK for initiation treatment, marking a significant advancement in treatment convenience. LEQEMBI IQLIK is a subcutaneous auto-injector formulation that enables at-home administration, potentially reducing the burden of clinic visits and IV infusion requirements.
The treatment regimen for IQLIK involves 500 mg once weekly (two injections of 250 mg) for initiation treatment, compared to IV administration of 10 mg/kg every two weeks. After 18 months, patients can transition to maintenance treatment with 360 mg once weekly via IQLIK or 10 mg/kg every four weeks via IV, with the flexibility to switch between formulations.
Clinical evidence presented at the Alzheimer’s Association International Conference (AAIC) 2026 demonstrated that once-weekly subcutaneous administration showed similar exposure, clinical efficacy, and biomarker benefits to IV administration, with a comparable safety profile. Notably, 94% of users found the device easy or very easy to use without assistance.
The company outlined three key foundations for establishing LEQEMBI IQLIK’s treatment infrastructure in the United States: streamlining coverage and reimbursement processes, standardizing testing and benefits verification, and strengthening patient support for at-home administration. The commercial launch is planned for late August 2026.
Real-world evidence from the LEADER study, involving 432 patients with early AD across 13 clinical practices in the United States, demonstrated LEQEMBI’s long-term treatment value.
Among evaluable patients, 75.9% were clinically stable and 6.6% showed improvement, meaning 82.5% of patients were stable or improved. The treatment retention rate reached 86.6%, and among 204 patients treated for more than 18 months, 161 (78.9%) transitioned to maintenance treatment and remained on therapy.
Safety observations in the real-world setting were consistent with the FDA-approved label, with amyloid-related imaging abnormalities (ARIA) observed in 12.3% of patients, most of which were asymptomatic or mild in radiographic severity.
The evolution of the diagnostic pathway through blood-based biomarkers represents another strategic initiative to expand LEQEMBI’s addressable market.
The company is implementing BBM for both triage and confirmatory diagnosis, aiming to expand prescribing opportunities by standardizing amyloid beta diagnosis and improving patient access. BBM testing performed in the United States showed a 75% growth rate in FY2025, with significant increases in amyloid beta 42/40, pTau-181, and pTau-217 testing.
Projections indicate that BBM’s share of confirmatory diagnosis could increase from approximately 15% in FY2025 to 50% by FY2028, as the technology gains regulatory approval and clinical acceptance. The Alzheimer’s Association has included BBM in the CMS Anti-Amyloid Therapy Registry, and commercial testing became available as of July 2026.
Next-Generation Pipeline: Targeting the AD Continuum
Eisai’s long-term strategy centers on comprehensive drug discovery across the Alzheimer’s disease continuum, targeting amyloid, tau, and neurodegeneration pathologies with the stated goal to "make AD a curable disease."
The company’s anti-MTBR tau antibody etalanetug represents the next-generation approach to tau pathology. MTBR-tau243 has been included as a tau pathology biomarker in the Alzheimer’s Association’s biological diagnostic criteria, and measurement of plasma eMTBR-tau243 enables assessment of etalanetug’s pharmacodynamic effects.
Clinical data from the DIAD Phase Ib/II study demonstrated target engagement and proof of mechanism, with CSF eMTBR-tau243 showing a 62% reduction after three months and 89% reduction by nine months. Plasma eMTBR-tau243 demonstrated similar reductions of 78% at three months and greater than 90% by nine months. Tau PET imaging showed progression suppression or a trend toward reduction.
The clinical development program includes the Tau NexGen Phase II/III study evaluating etalanetug as an add-on to LEQEMBI in preclinical to early AD, with topline data expected in FY2028. A separate sporadic AD Phase II study (Study 202) in early AD patients is ongoing, with topline data expected in FY2027.
The company’s broader AD continuum strategy encompasses multiple intervention points:
For preclinical AD, the AHEAD3-45 study is evaluating lecanemab’s efficacy in preventing amyloid accumulation in a pure preclinical population, with the aim that AD "would not develop." The study involves 1,173 patients with global CDR=0 and amyloid accumulation >40 centiloids, using an optimized dosing regimen of biweekly IV administration for two years followed by once-monthly maintenance. Data readout is expected in FY2028.
The company estimates approximately 400 million people have preclinical AD globally, with 2.3 million potential patients eligible for AD disease-modifying therapies.
For neurodegeneration, Eisai is developing E2511, a TrkA integrated synapse regenerant for restoring neuronal function, and E2025, an anti-EphA4 antibody, both currently in Phase I development.
Orexin Pathway Platform Expansion
Beyond Alzheimer’s disease, Eisai is expanding its orexin pathway platform from sleep/wake regulation toward broader brain function network regulation. Lemborexant (DAYVIGO) serves as the foundation, with regulatory filings under review in the UK and EU for chronic insomnia.
The company is advancing ledasorexton (E2086), an orexin 2 receptor agonist, for narcolepsy treatment. A Phase I study (Study 101) in patients with narcolepsy type 1 demonstrated that once-daily administration significantly reduced excessive daytime sleepiness compared to both placebo and modafinil, with good tolerability and a favorable safety profile. A Phase II proof-of-concept study (Study 202) in narcolepsy types 1 and 2 is ongoing, with topline data expected in FY2026.
The company highlighted that the potential of orexin-based drug discovery is expanding beyond sleep/wake regulation to brain function networks that support daytime functioning, including cognition, behavior, and social participation.
Comprehensive Pipeline Overview
Eisai’s pipeline spans neurology and oncology, with multiple programs advancing toward key milestones over the next three fiscal years.
In neurology, beyond the programs already discussed, the company is advancing multiple formulations and indications for LEQEMBI, with regulatory decisions expected in Japan (Q2 FY2026) and China (Q4 FY2026-FY2027).
In oncology, beyond LENVIMA’s pending renal cell carcinoma indication, the company is developing taletrectinib (E7860), a ROS1 kinase inhibitor for ROS1-positive non-small cell lung cancer, with regulatory submissions completed in the EU and UK and an EU launch targeted for FY2027.
Serplulimab, an in-licensed anti-PD-1 antibody, is in development for extensive-stage small cell lung cancer, colorectal cancer, and perioperative gastric cancer, with a Japan submission planned for FY2026.
E7386, a CBP/β-catenin inhibitor being studied in combination with LENVIMA for solid tumors, is in Phase Ib/II development with topline data expected in FY2026.
Forward-Looking Statements and Market Outlook
Eisai maintained its full-year FY2026 forecast of ¥883.5 billion in revenue and ¥70.0 billion in operating profit. With first-quarter revenue reaching 26.5% of the annual target and operating profit at 35.3%, the company is tracking ahead of a linear pace, though management emphasized that the forecast remains unchanged.
The company’s product-specific forecasts include LENVIMA at ¥345.0 billion, DAYVIGO at ¥73.5 billion, and LEQEMBI at ¥143.5 billion for the full fiscal year.
Key near-term catalysts include the late August 2026 U.S. launch of LEQEMBI IQLIK for initiation treatment, the October 4, 2026 FDA PDUFA date for LENVIMA’s combination therapy in renal cell carcinoma, and regulatory decisions on DAYVIGO in the UK and EU.
For LEQEMBI specifically, the company is working to establish Medicare Part D formulary listing expected to begin in 2027, which could significantly expand patient access and reimbursement. The company is also advancing coverage and reimbursement negotiations with authorities across multiple countries in EMEA.
Despite the strong quarterly performance, the 3.56% stock decline to $4,656 suggests investors remain cautious about the company’s heavy spending trajectory and the timing of returns on its substantial investments in LEQEMBI infrastructure and next-generation pipeline programs. The shares now trade approximately 12.9% below their 52-week high of $5,349, though they remain 27.2% above the 52-week low of $3,660.
The company’s strategy of driving "sustainable corporate value enhancement through the dual engines of 3L growth and next-generation drug discovery" positions Eisai at the intersection of near-term commercial execution and long-term scientific innovation in neurology and oncology. Whether this dual approach can sustain investor confidence will depend on continued commercial momentum for the 3L products and successful advancement of the pipeline programs through clinical development and regulatory approval.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.